% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/cyp.R
\name{mech_stat_cyp_risk}
\alias{mech_stat_cyp_risk}
\title{CYP perpetration risk as per mechanistic-static modeling}
\usage{
mech_stat_cyp_risk(
  perp,
  cyp_inh,
  cyp_ind,
  cyp_tdi = NULL,
  d = 1,
  include_induction = TRUE,
  substr = cyp_reference_substrates,
  kdeg = cyp_turnover
)
}
\arguments{
\item{perp}{The perpetrator object.}

\item{cyp_inh}{CYP inhibition data as data frame, see
\link{basic_cyp_inhibition_risk} for details.}

\item{cyp_ind}{CYP induction data as data frame. See
\link{kinetic_cyp_induction_risk} for details.}

\item{cyp_tdi}{CYP TDI data as data frame. See \link{basic_cyp_tdi_risk}
for details.}

\item{d}{Induction scaling factor, defaults to 1.}

\item{include_induction}{Switch to define whether induction effects should be
included in the calculation (C-terms as per the FDA guideline)}

\item{substr}{The CYP probe substrates to be used as data frame, defaults to
\link{cyp_reference_substrates}. The data frame is expected to have the following
fields:
\itemize{
\item 'cyp' The CYP enzyme as (upper case) character.
\item 'substrate' The substrate name as character.
\item 'fgut' The fraction of the drug escaping gut metabolism.
\item 'fm' The fraction of the drug that undergoes hepatic metabolism.
\item 'fmcyp' The fraction metabolized by the respective CYP enzyme.
}}

\item{kdeg}{The CYP turnover data as data frame. Defaults to the
built-in reference data, \link{cyp_turnover}}
}
\value{
A data frame.
}
\description{
CYP perpetration risk as per mechanistic-static modeling
}
\details{
In this approach, AUC ratios for probe substrates are calculated based on
their known intestinal and hepatic metabolism. Both direct (competitive) and
time-dependent inhibition are considered.

The below formula given by the FDA guideline (refer to
fig. 7 of \href{https://www.fda.gov/media/134582/download}{FDA, 2020})
also includes intestinal and hepatic enzyme induction terms (\eqn{C_g} and
\eqn{C_h}, respectively). At the same time, the guideline states that both
inhibition and induction should be considered separately.

\deqn{AUCR = \frac{1}{A_g*B_g*C_g* \left(1-F_g \right)+F_g} * \frac{1}{A_h*B_h*C_h*f_m+\left(1-f_m\right)}}

The individual terms are:
\subsection{Reversible inhibition}{

\deqn{A_g = \frac{1}{1+\frac{I_g}{K_i}}}

\deqn{A_h = \frac{1}{1+\frac{I_h}{K_i}}}
}

\subsection{Time-dependent inhibition}{

\deqn{B_g = \frac{k_{deg,g}}{k_{deg,g} + \frac{I_g*k_{inact}}{I_g+K_I}}}

\deqn{B_h = \frac{k_{deg,h}}{k_{deg,h} + \frac{I_h*k_{inact}}{I_h+K_I}}}
}

\subsection{Induction}{

\deqn{C_g = 1 + \frac{d*E_{max}*I_g}{I_g+EC_{50}}}

\deqn{C_h = 1 + \frac{d*E_{max}*I_h}{I_h+EC_{50}}}

with the hepatic inlet concentration \eqn{I_h=I_{max,inlet,u}} and the
intestinal concentration \eqn{I_g=I_{enteric,u}}, see
\code{\link[=key_concentrations]{key_concentrations()}}.

\eqn{d} is a scaling factor for the CYP induction term with a standard value
of 1. A different value can be used if warranted by prior experience with the
experimental setup.
}
}
\examples{
mech_stat_cyp_risk(examplinib_parent, examplinib_cyp_inhibition_data,
  examplinib_cyp_induction_data)
mech_stat_cyp_risk(examplinib_parent, examplinib_cyp_inhibition_data,
  examplinib_cyp_induction_data, examplinib_cyp_tdi_data)
mech_stat_cyp_risk(examplinib_parent, examplinib_cyp_inhibition_data,
  examplinib_cyp_induction_data, examplinib_cyp_tdi_data,
  include_induction = FALSE)
}
\seealso{
\code{\link[=mech_stat_cyp_risk_table]{mech_stat_cyp_risk_table()}}

\link{cyp_reference_substrates}

\link{cyp_turnover}
}
